Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 24, 2017

View Archived Issues

Janssen describes anxiolytic candidate JNJ-54717793, a selective Ox1R antagonist

Genentech discovers new, potent and selective inhibitors of Nav1.7

Grid Therapeutics signs license agreement with Duke University for CFH antibodies for cancer

Inactivation of PERVs to eliminate cross-species viral transmission in xenotransplantation

Novel VLP zDIII-based subunit Zika vaccine demonstrates high immunogenicity in mice

Teikoku Pharma reports topline phase II results for TPU-006 patch in post-surgical pain

Apic Bio launches with focus on therapies for alpha-1 antitrypsin deficiency

GT Biopharma announces reverse stock split

Novel series of GyrB/ParE inhibitors discovered for bacterial infections including gonorrhea

Cure Pharmaceutical reports progress in development of ODS formulation of isoniazid

FDA grants orphan drug designation to EPX-300 for Dravet syndrome

Emcure Pharmaceuticals presents new IDO-1, TDO inhibitors

Intra-Cellular Therapies receives FDA opinion on lumateperone program in schizophrenia

Novel retinoic acid receptor ligands discovered at Galderma

ViiV Healthcare divulges new HIV maturation inhibitors

Bamichem, Samjin Pharmaceutical, Incheon National University patent VEGFR-2, B-Raf, C-Raf inhibitors

GlaxoSmithKline discovers new phosphatidylinositol 3-kinase inhibitors

Caprion collaborates with FNIH Biomarkers Consortium on Cerebrospinal Fluid Proteomics Project

Otsuka and Mylan sign delamanid license agreement for low- and middle-income countries

Symic Bio initiates phase II MODIFY2 study of SB-061 for osteoarthritis

E.U. approval for Kisqali with an aromatase inhibitor for first-line HR+/HER- breast cancer

ImmunoCellular refocuses resources on Stem-to-T-Cell research program

FDA grants priority review to emicizumab BLA for hemophilia A

Orchard's OTL-101 designated Promising Innovative Medicine in U.K. for ADA-SCID

First-in-human study evaluates fluorothyazinone in healthy volunteers

Daewoong studies DWP-14012 for erosive GERD in new phase II trial

Bonti initiates phase II LANTERN-1 study of EB-001 to reduce musculoskeletal pain

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 10, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...